Europos Sąjunga - islandų - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - skjaldkirtilsæxli - Æxlishemjandi lyf - meðferð hjá fullorðnum sjúklingum með framsækið, óleysanlegt, staðbundið langt gengið eða meinvörpað skjaldkirtilskrabbamein.

Europos Sąjunga - islandų - EMA (European Medicines Agency)

hra pharma rare diseases - ketókónazól - cushing heilkenni - sveppalyf fyrir almenn nota - ketókónazól hra er ætlað til meðferðar við cushing heilkenni hjá fullorðnum og unglingum eldri en 12 ára.

Europos Sąjunga - islandų - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 2,5 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg /12,5 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 5 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 20 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 10 mg

Europos Sąjunga - islandų - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - flogaveiki - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Europos Sąjunga - islandų - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - sýklalyf - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.